Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC, Warfarin and Non-Anticoagulated Patients.
Clinical takeawayRisk-stratify GI bleeding on severity and patient factors (age, shock, renal failure) rather than anticoagulant status; the anticoagulant estimates were imprecise (30-day OR 1.61, 95% CI 0.81-3.21 for DOAC), so a modest effect is not excluded.
What it foundNeither DOAC nor warfarin was significantly associated with 30-day or 1-year mortality after GIB (30-day OR 1.61, 95% CI 0.81-3.21 for DOAC; 1.30, 95% CI 0.56-3.02 for warfarin).
ContextChallenges the assumption that anticoagulation status drives mortality in GIB, refining risk stratification to include clinical presentation and comorbidities.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Forkosh E … Talmon A · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗